Donanemab-azbt Approved for Early Symptomatic Alzheimer Disease.

Autor: Biello Jr, Domenic M.1, Chamberlin, Kevin W.2
Zdroj: Drug Topics. Nov/Dec2024, Vol. 168 Issue 8, p27-27. 1p.
Databáze: Business Source Ultimate
Externí odkaz: